- 20 Apr 2018
- Positive Data on Osteoarthritis Gene Therapy Generated by GeneQuine and Collaborators Presented at OARSI World Congress (26 – 29 April 2018, Liverpool)
- 12 Apr 2018
- GeneQuine to attend Biopartnering and Investment Conference BioTrinity in London April 23 – 25, 2018
GeneQuine Biotherapeutics GmbH develops novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need.
Osteoarthritis is the most common joint disorder in humans as well as in animals such as horses and dogs. Since long-term efficient medicines are currently not available, osteoarthritis represents a significant unmet medical need.
GeneQuine's mission is to improve patients' mobility and quality of life by revolutionizing the treatment of osteoarthritis. In order to achieve this, GeneQuine uses the latest knowledge in the field to identify the most suitable base technology for ideal osteoarthritis drugs. GeneQuine found that a gene therapy approach is ideally suited to deliver long lasting effective and safe treatment of osteoarthritis. Therefore, GeneQuine based its drug candidates on an innovative gene therapy approach utilizing next generation gene transfer vehicles.
In parallel to the development of osteoarthritis drugs for humans, GeneQuine develops products for the veterinary field. Veterinary drug development is a highly attractive area as regulatory hurdles, product development risk as well as development costs are markedly lower and market approval can be gained faster compared with the human sector. GeneQuine is focused on gaining market authorization for its gene therapy products for treatment of osteoarthritis in horses and dogs.
In December 2017, GeneQuine sold the lead program GQ-203 (now designated FX201) for the treatment of osteoarthritis in humans to Flexion Therapeutics, Inc. GeneQuine retains the rights to all other development programs listed in the pipeline overview.